Chronic obstructive pulmonary disease (COPD) has an insidious onset and causes disabling symptoms. This article discusses its risk factors, pathophysiology, assessment, interventions, and nursing…
On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm in patients…
Chronic obstructive pulmonary disease (COPD) has an insidious onset and causes disabling symptoms. This article discusses its risk factors, pathophysiology, assessment, interventions,…
On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm…